



July 7, 2017

BSE Limited
Floor 25, P. J. Towers
Dalal Street,
Mumbai - 400 001

National Stock Exchange of India Limited
Exchange Plaza
Bandra Kurla Complex
Bandra (E)
Mumbai - 400 051

Dear Sir,

As per Regulation 13(3) of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we enclose the statement of Investor complaints for the quarter ended June 30, 2017.

Kindly take the same on record.

Thanking you,

Yours faithfully,
For Jubilant Life Sciences Limited


Rajiv Shah
Company Secretary

Encl.: as above

A Jubilant Bhartiya Company

OUR VALUES



Jubilant Life Sciences Limited

1-A, Sector 16-A,
Noida-201 301, UP India
Tel: +91 120 4361000
Fax: +91 120 4234895-96
www.jubl.com

Regd Office:
Bhartiagram, Gajraula
Distt. Amroha - 244 223,
UP India
CIN : L24116UP1978PLC004624



**STATEMENT OF INVESTOR COMPLAINTS FOR THE
QUARTER ENDED JUNE 30, 2017**

[Pursuant Regulation 13(3) of the Securities and Exchange Board of India
(Listing Obligations and Disclosure Requirements) Regulations, 2015]

1. Name of Listed Entity Jubilant Life Sciences Limited
2. Quarter ending June 30, 2017

Sr. No.	Particulars	Details
1.	Number of Investor complaints pending at the beginning of the quarter ended June 30, 2017	0
2.	Number of Investor complaints received during the quarter ended June 30, 2017	1
3.	Number of Investor complaints disposed of during the quarter ended June 30, 2017	1
4.	Number of Investor complaints remaining unresolved at the end of the quarter ended June 30, 2017	0

For Jubilant Life Sciences Limited

Rajiv Shah
Company Secretary

1.-

JS